This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
Market Strategy: Archive
Sell-Side and Buy-Side - Consensus at a Glance
by John Blank
A valuation boost from the attraction of a broad equity risk premium looks OK using Zacks 2025 S&P500 earnings of $275.08.
asset-allocation
Zacks FX 3-Part Consensus to DEC 2025
by John Blank
An index of U.S. companies may lead one to initially assume that the S&P 500 is exclusively dependent on the health of the U.S. economy. In reality, the index is more global than one may think.
asset-allocation
SGU Q4 Loss Wider Than Expected, Revenues Drop 10% Amid Cost Cuts
by Zacks Equity Research
Star Group faces a challenging quarter with revenues down 10% and wider losses. Improved cash reserves and strategic investments aim to offset headwinds.
SGUPositive Net Change
earnings tech-stocks
VLGEA's Q1 EPS Up 10% Y/Y, Digital Sales Drive 4% Revenue Growth
by Zacks Equity Research
Village Super Market posts fiscal Q1 EPS growth driven by digital sales, pharmacy sales and remodeled store success.
VLGEANegative Net Change
earnings retail
Zacks Initiates Coverage of AstroNova With Neutral Recommendation
by Debasmita Chatterjee
Discover why Zacks has given AstroNova a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Explore the company's eco-friendly printing innovations and operational efficiencies alongside challenges from rising debt.
ALOTPositive Net Change
business-services
Zacks Initiates Coverage of ImmuCell With Neutral Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates ImmuCell as "Neutral." Explore ImmuCell's market leadership, growth prospects and the game-changing potential of its mastitis treatment nearing FDA approval.
ICCCPositive Net Change
medical
Zacks Initiates Coverage of Jones Soda With Neutral Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates Jones Soda as "Neutral." Explore how JSDA navigates opportunities with health-focused and cannabis-infused drinks despite financial challenges.
JSDANo Net Change
consumer-staples
Zacks Initiates Coverage of NetSol With Outperform Recommendation
by Urbashi Dutta
Discover why Zacks, being the first on Wall Street to initiate the stock coverage, rates NTWK as "Outperform." Explore NetSol's growth potential with major global contracts and innovative tech, positioning it for success in asset finance and leasing solutions.
NTWKNegative Net Change
tech-stocks
Zacks Initiates Coverage of NRC Health With Neutral Recommendation
by Debasmita Chatterjee
Discover why Zacks has given NRC Health a "Neutral" rating, being the first on Wall Street to initiate coverage on the stock. Dive into the company's AI innovations, strategic partnerships, and financial resilience, along with the challenges of revenue declines, rising debt and stiff competition.
NRCNegative Net Change
business-services
Two Smaller Companies Worthy of Your "Attention"
by Mark Zinski
Here we highlight a small cap and a microcap with Zacks Outperform ratings.
ELTPNegative Net Change PRPONo Net Change
genomics pharmaceuticals small-cap
La Rosa Posts 188% Y/Y Revenue Surge in Q3, Faces Loss Amid Expansion
by Zacks Equity Research
LRHC reports strong y/y revenue growth in Q3. However, it struggles with rising losses and debt as it expands its agent network and services.
LRHCNegative Net Change
earnings multi-sector-conglomerates
AgEagle Aerial Posts Narrower Y/Y Loss in Q3, Mixed Performance
by Zacks Equity Research
UAVS's Q3 results reflect a narrowed y/y loss, an improved gross margin and strong cost control despite a revenue decline and ongoing liquidity challenges.
UAVSPositive Net Change
consumer-staples earnings
Cato Incurs Wider Q3 Loss, Sales Drop Y/Y Amid Operational Challenges
by Zacks Equity Research
CATO posts a wider year-over-year loss in Q3 and 8% sales drop as hurricanes, supply chain woes, and rising costs weigh on results. Challenges are expected to persist.
CATOPositive Net Change
earnings retail
GEOS Stock Declines After Q4 Earnings Amid Mixed Segment Performance
by Zacks Equity Research
Geospace posts a loss in the fourth quarter of fiscal 2024 despite revenue growth in the Adjacent Markets segment.
GEOSPositive Net Change
earnings electronics tech-stocks
Blue Dolphin Q3 Earnings & Revenues Decline Y/Y Amid Weaker Margins
by Zacks Equity Research
BDCO reports a y/y Q3 revenue drop and net loss due to weaker refining margins, lower sales volumes and inventory impairments.
BDCONegative Net Change
earnings energy oil-energy
Monarch Cement Q3 Earnings Surge Y/Y Amid Strong Market Demand
by Zacks Equity Research
MCEM posts robust Q3 results with higher sales, improved EPS and significant equity gains, outperforming the market by a wide margin.
MCEMNegative Net Change
construction earnings
Applied Energetics Q3 Loss Widens Y/Y, Revenues & Costs Rise
by Zacks Equity Research
AERG posts higher revenues but faces wider losses due to rising costs while securing key defense contracts and expanding operations.
AERGNegative Net Change
earnings tech-stocks
PrimeEnergy Posts Y/Y Earnings Growth in Q3 on Surging Oil Production
by Zacks Equity Research
PNRG's Q3 earnings skyrocket y/y with a 134% jump in oil production, robust revenue growth, and asset sales fueling long-term expansion plans.
PNRGNegative Net Change
earnings energy oil-energy
TSS Reports 900% Y/Y Earnings Surge in Q3, Bolsters AI Integration
by Zacks Equity Research
TSSI delivers record Q3 results, with a 689% y/y revenue surge, driven by AI-enabled rack integration and procurement services.
TSSINegative Net Change
earnings industrial-products
Inspire Veterinary Partners Reports Narrower Y/Y Loss Amid Revenue Dip
by Zacks Equity Research
IVP reports 56% narrower y/y Q3 loss, cuts costs and boosts efficiency despite a revenue dip.
IVPPositive Net Change
consumer-staples earnings
Syntec Optics Stock Drops 36% Since Q3 Earnings Release, Sales Up Y/Y
by Zacks Equity Research
OPTX's earnings break even in Q3 and decline year over year. Revenue rise 19.2% year over year, boosted by data center and night vision demand.
OPTXPositive Net Change
business-services earnings
ImmuCell Q3 Earnings Decline Y/Y, Sales Grow Amid Margin Challenges
by Zacks Equity Research
ICCC sees strong Q3 sales growth but faces challenges with margins. It awaits FDA approval for its groundbreaking Re-Tain product.
ICCCPositive Net Change
earnings medical
Smith-Midland Q3 Earnings Skyrocket 146% Y/Y, Revenues Soar 51%
by Zacks Equity Research
Smith-Midland posts Q3 revenues of $23.6 million, driven by service growth and higher margins, boosting earnings per share to 59 cents.
SMIDPositive Net Change
construction earnings
Nova LifeStyle Stock Falls Despite Q3 Earnings Uptick Y/Y, Revenues Up
by Zacks Equity Research
NVFY reports third-quarter losses as operational costs rise. Sales growth in North America offers a glimmer of hope.
NVFYNegative Net Change
consumer-discretionary earnings
MiT's Earnings Break Even in Q1 Amid Revenue and Demand Struggles
by Zacks Equity Research
MITQ posts Q1 breakeven earnings with a 20.8% revenue decline, impacted by post-COVID recovery challenges and softer demand, while maintaining R&D investments to drive future growth.
MITQNegative Net Change
business-services earnings